Clare Craig on Medical Ethics
2:35 Mosquirix is a trade name for RTS,S/AS01:
In a bid to accommodate a larger group and guarantee a sustained availability for the general public, GSK applied for a marketing license with the European Medicines Agency (EMA) in July 2014. GSK treated the project as a non-profit initiative, with most funding coming from the Gates Foundation, a major contributor to malaria eradication.
In July 2015, Mosquirix received a positive scientific opinion from the European Medicines Agency on the proposal for the vaccine to be used to vaccinate children aged 6 weeks to 17 months outside the European Union.
See also John Campbell on the UK Biobank Dataset and the BBC.
Subscribe to Clare Craig.
Comments
Post a Comment